Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Feb 8, 2022Organizations including Superhuman Use BD Veritor™ At-Home COVID-19 Test with the ReturnSafe Platform to Keep Employees Safe at WorkBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with ReturnSafe, the all-in-one software solution for COVID-19 employee...
-
Feb 3, 2022- Revenue of $5.0 billion declined 6.0% as reported and 5.9% on currency-neutral basis, due to a decline in worldwide COVID-only testing revenues to $185 million from $866 million in the prior year
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal year 2022, which ended December 31, 2021. "Our...
Feb 1, 2022BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has approved the planned spinoff of its diabetes care business,...
-
Feb 1, 2022Informatics Capabilities Help Expand BD Data Analytics Capabilities and Understanding of Cancer and Other Chronic Diseases
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of Cytognos, a privately held company headquartered in...
-
Jan 27, 2022Company Included in 2022 Bloomberg Gender-Equality Index and Named Best Place to Work for LGBTQ+ Equality from The Human Rights Campaign Foundation
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been included in the 2022 Bloomberg Gender-Equality Index (GEI) for the...
Jan 26, 2022Study uses real-world data to demonstrate the effectiveness of vaginal panel performed on the BD MAX™ System compared to clinicians' assessmentsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the outcome of a peer-reviewed study published in the journal of Obstetrics &...
-
Jan 25, 2022
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.87 per common share, payable on March 31, 2022 to holders of record on March 10,...
Jan 20, 2022Technology Breakthrough Has Potential to Transform Wide Range of Disciplines from Immunology and Genomics Research to Cell-Based TherapeuticsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that a study conducted in collaboration with the European Molecular Biology Laboratory...
Jan 11, 2022JUST 100, the Only Ranking that Recognizes Companies Doing Right by All Their Stakeholders as Defined by the American Public, Acknowledges BD's Commitment to Environmental, Social and Governance PerformanceBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it was named to the JUST 100 list of America's most just companies by JUST Capital and...
Jan 11, 2022Joint Effort Will Highlight How Diagnostic Best Practices Can Improve Patient Care, Clinical Practice and Health Care EconomicsBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with Pfizer Inc. and global charitable foundation Wellcome to better...